3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
29
Stomach Neoplasms
25
Rectal Neoplasms
25
Colonic Neoplasms
13
Neoplasm Metastasis
3
Adenocarcinoma
3
Neoplasms
2
Gastrointestinal Neoplasms
2
Recurrence
1
Peripheral Nervous System Diseases
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Rectal Cancer
1
Locally Advanced Gastric Cancer
1
Locally Advanced Colorectal Cancer
1
Intestinal Neoplasms
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
HER2-positive Colorectal Cancer
1
Gastrointestinal Diseases
1
Gastric Cancer Stage
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Colorectal Cancer Metastatic
1
Colonic Diseases
1
Carcinoma
1
Interventions
Oxaliplatin
10
Gemcitabine
8
Cisplatin
7
Hepatectomy
6
Fluorouracil
6
Radiofrequency Ablation
5
Liver Transplantation
5
Irinotecan
5
Capecitabine
5
lenvatinib
4
Paclitaxel
4
Neoadjuvant Therapy
4
Folfox protocol
4
Cetuximab
4
Aspirin
4
tislelizumab
3
Surgical Procedures, Operative
3
Nivolumab
3
Carboplatin
3
titanium silicide
2
durvalumab
2
apatinib
2
Trastuzumab
2
S 1 (combination)
2
Leucovorin
2
Lamivudine
2
Introns
2
Ethiodized Oil
2
Drug Therapy
2
DNA, Mitochondrial
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
XELOX
×
Gastrointestinal
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled